Company Research Report: Rhythm Pharmaceuticals, Inc.

Company Overview

• Name: Rhythm Pharmaceuticals, Inc.

• Mission: Transform the lives of patients with rare neuroendocrine diseases by rapidly advancing care and precision medicines that address the root cause.

• Founded: 2008

• Founder(s): No specific individual founders listed in the data provided.

• Key People:

• No detailed information available about key individuals from the provided data.

• Headquarters: 222 Berkeley Street, 12th Floor, Boston, MA 02116, United States.

• Number of Employees: More than 250 employees in North America and Europe.

• Revenue: No information is available.

• Notable For: Specializing in treatments for rare neuroendocrine diseases, focusing on conditions related to the melanocortin-4 receptor (MC4R) pathway.

Products

• IMCIVREE® (setmelanotide):

• Description: A precision medicine designed to treat severe obesity caused by rare conditions linked with disruptions in the MC4R pathway.

• Key Features: Approved for treating obesity due to POMC and LEPR deficiency and Bardet-Biedl syndrome (BBS) in the US and Europe.

Recent Developments

• November 13, 2024:

• Rhythm Pharmaceuticals announced the publication of results from a Phase 3 study of Setmelanotide in patients aged between 2 and 5 years, published in The Lancet Diabetes & Endocrinology.

• Announcement of new employment inducement grants.

• November 06, 2024:

• Participation in upcoming investor conferences.

• 2024:

• First-ever patients dosed with RM-718.

• Acquired oral MC4R agonist LB54640 from LG Chem Life Sciences.

• 2023:

• Acquired Xinvento.

• Initiated Phase 3 trial in acquired hypothalamic obesity.

Research and Development

• Focus: Advancing genetic understanding to fuel MC4R pathway research and developing treatments for hyperphagia and severe obesity.

• Genetic Testing Program: Utilizing a significant DNA sequencing database from approximately 80,000 individuals to understand genetic underpinnings and target therapies for rare MC4R pathway diseases.

Note

• Additional Details: Contact Rhythm Pharmaceuticals via their official communication channels. Further insights on leadership figures and financial specifics may need access to investor relations content not available on restricted pages.

This report encapsulates the available insights from the data provided. For comprehensive information, direct engagement with Rhythm Pharmaceuticals' communications and investor relations departments would be beneficial.